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[ ]Vacc inat ion  coverage rates - a challenge for CF centers? 
L. Naehrlich, A. Stuppy. University hospital for children and adolescents, 
Erlangen, Germany 
Aims: Optimal vaccination coverage rates are important aims of public health and 
especially for CF-patients. On the other hand CF-patients may escape immunization 
programs due to exacerbations. To determine the vaccination coverage rates we 
review the vaccination status of our patients. 
Methods: We did a review of the vaccination records of our CF-patients and 
compared the results with the current national recommendations. We distinguish 
between pediatric (group R < 18 years) and adult (group A) patients. 
Results: 105 out of 118 patients over two years of age (88.9%) presented their 
immunization records. 72% percent were younger than 18 years (range 0.42 42.9. 
Median 12.08, 62% males and 38% females). Coverage of three doses of diphtheria, 
tetanus and poliomyelitis vaccination was > 97% (P) versus > 90% (A). The rate 
of age appropriate booster dose of diphtheria and tetanus were only 68% in 
adults. Cumulative coverage of measles, mumps, rubella (MMR) was > 94% (P) 
versus > 54% (A). Complete primary vaccinations of hepatitis B, pertussis and 
haemophilus influenzae type b was documented in > 85% (P). Coverage rates of 
even one dose of pneumococcal vaccination are 74% (P) versus 45% (A) and of 
influenza vaccination 76% (P) versus 55% (A). An unacceptable interval of the 
last booster dose was documented in 2% (P) versus 7% (A) for pneumococcal 
vaccination respectively 17% (P) versus 47% (A) for influenza immunization. 
Conclusions: High primary immunizations rates reflex the high acceptance of 
vaccinations. CF-centers hould been an advocate for pneumococcal nd influenza 
vaccination and time- or age-appropriate booster immunizations e pecially in adults 
and pre-transplant patients. 
An audit to identify the outcomes of an antibiotic desensitisation 
programme 
J. Redfern, M.E. Dodd, A.M. Jones, A.K. Webb. Manchester Adult CF Centre 
(MACFC), Manchester, UK 
Background: Patients (pts) with CF are exposed to repeated courses of high dose 
broad-spectrum antibiotics and reactions are frequently reported. Desensitisation 
(DS) is an option to try to maintain the choice of anti-bacterial agents available for 
that pt. The DS regimen at MACFC was altered in 2003 from a fixed concentration 
with increasing rates of administration to a fixed rate of administration with 
increasing concentrations. The change followed the antibiotic DS protocol described 
by Burrows et al (Respirology 2003 Sep;8(3): 359 64) at an adult CF centre, 
reporting a success rate of 76% 
Method: Pts were admitted electively to enable the DS regimen to be prepared in 
pharmacy. 7 bags were prepared containing dilutions ranging from the dose × 10 6 
up to the full dose. All doses were administered in 100ml NaC1 0.9% over 30 min- 
utes. Pts were closely monitored and intravenous adrenaline, chlorpheniramine and 
hydrocortisone were kept in the pt's room with a doctor always available on the 
ward. DS was avoided if pts had experienced a true anaphylactic reaction 
Results: 28 DS regimens were performed on 23 pts (5 pts were desensitised twice). 
75% of the DS regimens were successful. 6 pts have received subsequent courses 
of the antibiotic without further DS regimen. 1 pt, treated twice, had one initial 
unsuccessful and one subsequent successful DS on two separate admissions. 
Conclusion: Whilst DS is a time consuming procedure, it has enabled many patients 
to be treated with an antibiotic, which was previously not an available option. In 
addition the new regimen was easier to administer than the previous one with 
consequently less potential for error. 
13. Other issues 
l~An audit of adherence to prescribed Seretide ® by in-patients at 
an adult Cystic Fibrosis centre 
J. Redfern, M.E. Dodd, A.M. Jones, A.K. Webb. Adult CF Centre, South 
Manchester University Hospitals' NHS Trust (SMUHT), Manchester, UK 
Introduction: Patients at SMUHT are encouraged to bring their own medicines into 
hospital and to self-medicate during their stay. Cystic fibrosis patients, for various 
reasons, are reported as having a low adherence to prescribed therapy. An audit 
was designed to assess the level of adherence tousing Seretide ® accuhalers during 
an in-patient admission. Accuhalers are designed to record the number of doses 
remaining in the device, thus allowing adherence tobe assessed. 
Method: 50 cystic fibrosis patients on 3 wards were assessed over a period of 3 
months. The number of doses registered on the accuhaler was noted on admission 
and again on discharge. The number of doses used was compared to the number, 
which would have been used in the event of 100% adherence toprescribed therapy 
Results: see the table 
Adherence No. of patients % of patients 
100% 8 16 
75 100% 6 12 
50 75% 4 8 
25 50% 12 24 
1 25% 14 28 
0% 6 12 
Conclusion: This shows that 64% of patients had below 50% adherence with their 
inhaler therapy even during an in-patient stay 
Future Action: An education programme has now been started to improve patient 
knowledge regarding the mode of action of inhaled components. Additionally an 
assessment of inhaler technique is now performed at each admission and guidance 
given. This audit will then be repeated to identify if patient counselling on inhaled 
medicines and technique improves adherence. 
1~ Inappropriate routine prescribing in CF clinics 
M. Kanagarathnam, K. Mohan, C. Cowperthwaite, B. Govin, M.J. Walshaw, 
M.J. Ledson. Regional Adult CF Unit, The Cardiothoracic Centre, Liverpool, UK 
Introduction: In the UK, routine prescriptions for CF patients are provided by the 
primary care service. However, because of the special nature of some therapies, 
GPs may be unfamiliar with their prescription and retail pharmacies may find them 
difficult to source. Patients may therefore turn to CF clinics for their provision, 
increasing the drug costs in a sector where funding is often inadequate. To explore 
this further, we surveyed the prescription of routine drugs in our large CF clinic. 
Methods: All prescriptions for CF patients issued by our pharmacy in 2004 were 
reviewed. We excluded those for IV antibiotics and other acute treatments, and 
also for special theapies (e.g. Pulmozyme). The remaining scripts for routine repeat 
medications were costed and assessed on an individual patient basis. 
Results: Our pharmacy issued 627 CF prescriptions in 2004 (about 10% of the 
hospital total) for 130 patients (79% of the clinic). Of these, 102 patients (78%) 
obtained repeat prescriptions for routine CF medication: 24 patients had 5 or more 
prescriptions, and 15 had 8 or more. Commonest medications prescribed were 
Vitamin E (36 scripts), azithromycin (63), inhalers (64), Creon capsules (25) and 
multivitamins (20). Total cost of these scripts was £19,780. 
Conclusion: Some adult CF patients repeatedly obtain their routine prescriptions 
from the hospital. CF clinic funding arrangements do not take into account his 
burden, but many patients reported ifficulty in obtaining such medications in 
the community. Retail pharmacies in particular had problems ourcing vitamin 
E preparations, and some GPs supplied inadequate amounts of azithromycin and 
Creon. We are now working with primary care sector colleagues through our 
dedicated CF pharmacist to facilitate prescribing practices in the community. 
